TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02486978

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (109 g white bread)
Description: Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (109 g white bread)
Description: Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (109 g white bread)
Description: Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dose 1
Description: The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dose 2
Description: The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
Study: NCT03856853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: pirfenidone for SSc-ILD treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: as control
Study: NCT03370120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use
Study: NCT00507299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced pediatric primary care
Description: Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pediatric primary care
Description: Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
Study: NCT04269148

Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
Study: NCT02522676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Conventional PCNL will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Mini PCNL will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Ultra-mini PCNL will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Micro PCNL will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Retrograde intrarenal surgery will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive kidney stone treatment
Description: Extracorporeal shock wave will be performed.
Study: NCT05281107

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, 500 mg calcium
Description: Berry flavoured sachet powder (500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, 500 mg calcium
Description: Berry flavoured sachet powder (500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, 500 mg calcium
Description: Berry flavoured sachet powder (500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 500 mg calcium
Description: Berry flavoured sachet powder (500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 600 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 600 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 600 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 600 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1200 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1200 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1200 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1200 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 4000 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
Study: NCT01541189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
Study: NCT01805167

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological study of the interindividual variability of vocal performance
Study: NCT00464321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Study: NCT03526770

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: no intervention
Description: Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: tap water gargle
Description: The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: 0.2% Chlorhexidine
Description: The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 4: Fluoridated tooth paste
Description: The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 5: Polyol containing gum
Description: The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 6: 1% sodium bicarbonate solution
Description: The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study: NCT02443896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pit and Fissure Sealant of permanent molars
Description: The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No sealant of permanent molars
Description: No sealant applied to permanent molars.
Study: NCT02884063

Intervention type: PROCEDURE
Intervention: NGS reading for Media Free DNA
Description: NGS reading for Media Free DNA instead of blstomer biopsy

Intervention type: PROCEDURE
Intervention: NGS reading for Media Free DNA
Description: NGS reading for Media Free DNA instead of blstomer biopsy
Study: NCT05837442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Therapy
Description: Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
Study: NCT02888015

Intervention type: OTHER
Group type: OTHER
Intervention: upper extremity exercise program
Description: five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
Study: NCT03880487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-1199
Description: Single dose and Multiple ascending doses of KP-1199 oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Single dose and Multiple dose identical to active treatment but without KP-1199.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone oral capsule
Description: 10 mg Oxycodone Capsules
Study: NCT02730585

Intervention type: BIOLOGICAL
Intervention: C-reactive protein measurement
Description: All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
Study: NCT01967628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sugar Pill
Study: NCT04439604

Intervention type: OTHER
Intervention: regional ventilation monitoring
Description: regional ventilation monitoring
Study: NCT04496622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WBV technique
Description: Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration technique
Description: Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks
Study: NCT03628053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: autologous cellular immunotherapy product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blinatumomab
Description: bispecific CD19-directed CD3 T-cell engager

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotuzumab
Description: CD22-directed antibody-drug conjugate
Study: NCT00635479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC device
Description: Vacuum Assisted Closure (VAC) device for surgical incision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: Gauze dressing for surgical incision
Study: NCT01130285

Intervention type: GENETIC
Intervention: Lung Cancer Risk Test
Description: Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
Study: NCT02963116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 IR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 IR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 IR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin tablet
Study: NCT01075412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F18]Fluorothymidine
Description: FLT PET scan 5 mCi (+/- 10%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F18]Fluorothymidine
Description: FLT PET scan 5 mCi (+/- 10%)
Study: NCT04178759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Laparoscopic or open approach liver resection where at least 1 segment is removed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Laparoscopic or open approach liver resection where at least 1 segment is removed
Study: NCT03962738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02409849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide lar
Study: NCT02431091

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
Study: NCT02520323

Intervention type: OTHER
Intervention: Blood draw

Intervention type: OTHER
Intervention: Blood draw

Intervention type: PROCEDURE
Intervention: Bronchoscopy

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Study: NCT00530283

Intervention type: OTHER
Intervention: PET-CT
Study: NCT02243254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose remifentanil
Description: high dose remifentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: high dose remifentanil
Description: high dose remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: intravenous ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: intravenous ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose remifentanil
Description: low dose remifentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low dose remifentanil
Description: low dose remifentanil
Study: NCT04579562

Intervention type: OTHER
Intervention: No intervention
Description: This is observational, non-interventional study

Intervention type: OTHER
Intervention: No intervention
Description: This is observational, non-interventional study

Intervention type: OTHER
Intervention: No intervention
Description: This is observational, non-interventional study
Study: NCT04185753

Intervention type: DIAGNOSTIC_TEST
Intervention: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
Description: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

Intervention type: DIAGNOSTIC_TEST
Intervention: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
Description: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
Study: NCT03750578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality goggle (Oculus Rift ® Helmet)
Description: as described
Study: NCT04026178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
Study: NCT03807804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLCM051
Description: HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLCM051
Description: HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
Study: NCT01242267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide+Melphalan +Bortezomib+stem cell transplant
Description: Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide+Melphalan +Bortezomib+stem cell transplant
Description: Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
Study: NCT02887404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spine surgery analgesic pathway
Description: Enhanced pain management care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of pain management care
Study: NCT01012102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 640744
Description: EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 640744
Description: EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 640744
Description: EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
Study: NCT03048539

Intervention type: PROCEDURE
Intervention: Transoral endoscopic thyroidectomy
Description: This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
Study: NCT03747211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: High Intensity Interval Training (HIIT)